AOD-9604 vs Semaglutide

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 is a synthetic fragment of the human growth hormone molecule, corresponding to amino acids 176–191 of the C-terminus. It is researched specifically for its lipolytic properties and is considered a lower-risk alternative to full growth hormone analogues for body composition research, given its apparent lack of effect on insulin sensitivity or IGF-1 levels.

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Its mechanism involves both peripheral and central appetite suppression.